Good news for patients with migraines.. "Vepti" is the first treatment offered by Ras Al Khaimah Hospital
Ras Al Khaimah Hospital announced that it has provided (Vepti) the first treatment to prevent migraines by inhibiting the peptide linked to the calcitonin gene, which reduces the period of suffering from migraines by up to 75%, and the hospital pointed out that 25% of the population of the country suffers from migraines, according to the report. Latest health reports.
Dr. Suita Adatya, a neurologist at Ras Al Khaimah Hospital, said that the new treatment for migraines is now available in Ras Al Khaimah Hospital, by providing a treatment called intravenous (Vipti) that is given to the patient in four doses annually, and each dose lasts 30 minutes.
She explained that patients have the opportunity to choose from three different categories of anti-peptide treatments related to the calcitonin gene that are provided by the hospital, the latest of which is the Vipti treatment, where the other two treatments are given Imovig (Ernumab) and Emgaliti (galcanizumab) subcutaneously once a month. The most important migraine treatment and prevention method for decades has been designed to target calcitonin-binding peptide, a protein known to cause migraine attacks, by inhibiting the peptide's activity by a monoclonal antibody in the drug.
She added that in the absence of a drug designed to prevent migraines, doctors treat even cases of migraine using preventive drugs, such as antidepressants, epilepsy drugs and anti-hypertensives, but anti-peptide drugs linked to the calcitonin gene target the root cause of the problem and benefit patients greatly by reducing The period of suffering from migraine headaches by 50-75%.
She stated that the peptide linked to the calcitonin gene is present in the brain, and it is the main cause of pain, as the hospital launched its first antidote treatment in mid-2020 by prescribing treatment on a large scale for patients who all witnessed a clear improvement in their quality of life, and accordingly the hospital had sufficient experience in providing treatments The three anti-peptides linked to the calcitonin gene, including the "Vepti" treatment, are given as an intravenous injection every three months.
She added that monoclonal antibodies are tested to detect migraine with pre-warning, migraine without prior warning, episodic migraine, chronic migraine and headache caused by overuse of medications. People who have not improved with preventive methods should try them.
He pointed out that migraine is one of the diseases that are not diagnosed and treated appropriately in most cases, which negatively affects all aspects of patients' lives, especially the personal and professional aspects, as it affects the patient's quality of life and leads to a decline in his productivity and ability to carry out daily tasks, as well as Negative society view of him.
She explained that 25% of the country's population, with an average of 1 in 4 people, suffers from migraines, although many cases have not been diagnosed over a long period of time.
According to health data, the treatment period takes about 5 years, on average, from the appearance of the first clinical symptoms until the correct diagnosis of a migraine case.
Adatya added, "More than 100 patients who suffer from headaches visit our outpatient clinics every month, 60% of whom suffer from migraine, and it is known that females constitute 70% of migraine patients compared to 30% of males.
She explained, "A patient's migraine attack can last from four hours to three days and may cause severe exhaustion and be associated with head pain, palpitations, nausea, vomiting, sensitivity to light and sound, and some patients may have to spend from 15 to 18 days of the month in dark rooms because of headache attacks." Migraines that can lead to a disability affect a person's ability to function normally.
And she added that some people may have warning symptoms known as an aura that precedes or accompanies a headache, and these symptoms can include visual disturbances, such as seeing flashes of light or blind spots, or other disturbances, such as feeling tingling in one side of the face or in the arm. or leg and difficulty speaking.
For his part, the CEO of Ras Al Khaimah Hospital, Dr. Reda Seddiqi, said, "The new treatment methods are considered the best for patients who suffer from migraines, and Ras Al Khaimah Hospital is one of the first health institutions that provide all options for patients in the country.
In turn, patient Amy May Schenk, who has seen remarkable results with the new anti-peptide treatment associated with the calcitonin gene, said, “I feel like a completely different person who started her life again. After suffering for 13 years, she consulted many doctors and specialists and tried a full range of treatments.” including acupuncture, chiropractic sessions, mouthguards, and more, until I fell into despair and succumbed to the pain, but the new treatment put an end to my suffering.
She explained, "Since I started receiving intravenous vepti (aptensmab), my headaches have decreased from once a day to once a week, as I have suffered in the past from severe pain and vision problems in addition to daily vomiting and nausea, but I am now able after several years To spend quality time with my family and continue my studies, which was scary for me because of my health condition.
Follow our latest local and sports news and the latest political and economic developments via Google newsKeywords: